Diagnostic efficiency of hybrid imaging using PSMA ligands, PET/CT, PET/MRI and MRI in identifying malignant prostate lesions

Sergiu Scobioala1,4 · Christopher Kittel1,4 · Heidi Wolters3,4 · Sebastian Huss2,4 · Khaled Elsayad1,4 · Robert Seifert3,4 · Lars Stegger3,4 · Matthias Weckesser3,4 · Uwe Haverkamp1,4 · Hans Theodor Eich1,4 · Kambiz Rahbar3,4

Received: 25 February 2021 / Accepted: 10 March 2021 / Published online: 19 March 2021
© The Author(s) 2021

Abstract

Objective The objective of this study was to assess the accuracy of 68Ga-PSMA-11 PET/MRI, 18F-PSMA-1007 PET/CT, 68Ga-PSMA-11 PET/CT, and multiparametric (mp)MRI for the delineation of dominant intraprostatic lesions (IPL).

Materials and methods 35 patients with organ-confined prostate cancer who were assigned to definitive radiotherapy (RT) were divided into three groups based on imaging techniques: 68Ga-PSMA-PET/MRI (n = 9), 18F-PSMA-PET/CT (n = 16) and 68Ga-PSMA-PET/CT (n = 10). All patients without PSMA-PET/MRI received an additional mpMRI. PSMA-PET-based automatic isocontours and manual contours of the dominant IPLs were generated for each modality. The biopsy results were then used to validate whether any of the prostate biopsies were positive in the marked lesion using Dice similarity coefficient (DSC), Youden index (YI), sensitivity and specificity. Factors that can predict the accuracy of IPLs contouring were analysed.

Results Diagnostic performance was significantly superior both for manual and automatic IPLs contouring using 68Ga-PSMA-PET/MRI (DSC/YI SUV70%—0.62/0.51), 18F-PSMA-PET/CT (DSC/YI SUV70%—0.67/0.53) or 68Ga-PSMA-PET/CT (DSC/YI SUV70%—0.63/0.51) compared to mpMRI (DSC/YI—0.47/0.41; p < 0.001). The accuracy for delineating IPLs was not improved by combination of PET/CT and mpMRI images compared to PET/CT alone. Significantly superior diagnostic accuracy was found for large prostate lesions (at least 15% from the prostate volume) and higher Gleason score (at least 7b) comparing to smaller lesions with lower GS.

Conclusion IPL localization was significantly improved when using PSMA-imaging procedures compared to mpMRI. No significant difference for delineating IPLs was found between hybrid method PSMA-PET/MRI and PSMA-PET/CT. PSMA-based imaging technique should be considered for the diagnostics of IPLs and focal treatment modality.

Keywords Prostate cancer · PSMA-PET · Multiparametric MRI · Hybrid imaging · Biopsy-derived landmarks

Introduction

Accurate delineation of the malignant intraprostatic lesions (IPLs) can be performed using advanced molecular imaging procedure as positron emission tomography (PET) technology and multiparametric (mp) MRI. Previous studies showed superior accuracy of [11C]-choline-PET/CT images compared to MRI for delineating IPLs [1–4]. Diagnostic performance of PET-CT methods for delineating IPLs was considerably improved with introduction of PSMA ligands such as 68Ga-PSMA and 18F-PSMA [5–10]. Recent studies evaluated the hybrid imaging tool 68Ga-PSMA-PET/MRI and 18F-PSMA-PET/MRI for the diagnostics of primary or recurrent prostate cancer (PCa) [6, 11–13]. It is expected that PSMA-PET/MRI should deliver higher
diagnostic accuracy because it combines molecular, functional and morphological information [10]. As reported by Kim et al., the 18F-PSMA-PET/MRI provided higher detection rate of PCa than other imaging procedures [13]. Eiber et al. received superior accuracy for identifying the IPLs using 68Ga-PSMA-PET/MRI compared to stand alone 68Ga-PSMA-PET and mpMRI [6]. To date, the accuracy of PET or MRI imaging for delineating IPLs was evaluated using prostatectomy specimens as standard of reference [1, 2, 4, 6–8, 14]. Alternatively, for the purposes of radiotherapy (RT) planning with focal dose escalation on tumour areas within the prostate, the methodologies utilizing the biopsy-derived prostate specimens should be evaluated. In addition, RT concepts for primary PCa using image-guided focal boost treatment need an optimal diagnostic algorithm for localizing malignant IPLs. The present study evaluates diagnostic performance for identifying IPLs analysing the 68Ga-PSMA-PET/MRI, as well as 18F-PSMA-PET/CT and 68Ga-PSMA-PET/CT alone or in combination with mpMRI using the prostate biopsy specimens for the validation of diagnostic accuracy of images. In addition, parameters that can potentially predict the accuracy of PSMA-PET and MRI images for delineating IPLs were analysed.

Materials and methods

Patients and study strategy

This study is based on the analysis of 35 patients with low-to-high risk prostate carcinoma who were treated by external beam RT between years 2013 and 2019 in our department. The median age was 68 years (range 58–77 years) and the median pre-imaging PSA was 15.4 ng/mL (range 0.6–57.9 ng/mL). The patient, prostate carcinoma and imaging characteristics are presented in detail in Table 1. The patients were divided into three groups in dependence of performed imaging procedures: 68Ga-PSMA-PET/MRI (n = 9), 18F-PSMA-PET/CT (n = 16) and 68Ga-PSMA-PET/CT alone of in combination with mpMRI. Additionally, 68Ga-PSMA-PET/CT alone or in combination with mpMRI were used for the prostate biopsy specimens for the validation of diagnostic accuracy of images. In addition, parameters that can potentially predict the accuracy of PSMA-PET and MRI images for delineating IPLs were analysed.

Image acquisition

68Ga-PSMA-11 and 18F-PSMA-1007 precursors were obtained from ABX (Advanced Biochemical Compound, Radeberg, Germany) and produced according to standard

Table 1 Characteristics of variables: patients, tumour, radiological method

| Parameter | n (%) | range |
|-----------|-------|-------|
| No. of patients | 35 (100) | |
| Median age/range, years | 68/58–77 | |
| Median prostate volume/range, cc | 31/21–54 | |
| Pre-imaging PSA median/range, ng/mL | 15.4/0.6–57.9 | |
| T stage | |
| cT1c | 15 (43) |
| cT2a | 7 (20) |
| cT2b | 8 (23) |
| cT2c | 5 (14) |
| Prostate biopsy Gleason score | |
| 6 | 8 (23) |
| 7a | 6 (17) |
| 7b | 5 (14) |
| 8 | 10 (28) |
| 9 | 6 (17) |
| Radiological method | |
| 68Ga-PSMA-PET/CT + mpMRI | 10 (28) |
| 18F-PSMA-PET/CT + mpMRI | 16 (46) |
| 68Ga-PSMA-PET/MRI | 9 (26) |
| mpMRI | 26 (74) |
| SUV values | |
| SUVmax | 68Ga-PSMA-PET/CT | 8.2 (2.6–19.2) |
| SUVmax | 18F-PSMA-PET/CT | 9.1 (2.1–21.4) |
| SUVmax | 68Ga-PSMA-PET/MRI | 7.8 (1.9–17.5) |
| SUV70% | 68Ga-PSMA-PET/CT | 15 (23)b |
| SUV70% | 18F-PSMA-PET/CT | 19 (27)b |
| SUV70% | 68Ga-PSMA-PET/MRI | 14 (22)b |
| Intraprostatic tumor volume (%)a | |
| 68Ga-PSMA-PET/CT | 18.3/6.8–70.4 |
| 18F-PSMA-PET/CT | 21.2/6.7–72.9 |
| 68Ga-PSMA-PET /MRI | 19.7/7.2–74.6 |
| T2W-MRI | 17.8/6.4–71.4 |
| DFW-MRI | 18.1/6.3–69.4 |
| DCE-MRI | 18.7/6.3–68.5 |
| Number of selected prostate lesionsc | |
| 68Ga-PSMA-PET/CT + mpMRI | 21 |
| 18F-PSMA-PET/CT + mpMRI | 33 |
| 68Ga-PSMA-PET/MRI | 17 |

PSA prostate-specific antigen, SUVmax maximum standardized uptake value, SUV70% 70% of the maximum SUV (defined as the best automatic contouring method), 18F-PSMA-1007 Gallium-18Fluoromethylcholine-prostate specific membrane antigen, PET positron emission tomography, mpMRI multiparametric magnetic resonance image, T2W T2-weighted, DFW diffusion-weighted, DCE dynamic contrast-enhanced

a Intraprostatic tumor volume relative to total prostate volume

b Percentage of SUV70% relative to all identified SUV-positive lesions

c Prostate lesions selected for the correlation analysis with a size of at least 1 cm3 and a SUV threshold of 3
operation procedure described before [15–19]. The main advantage of 18F-PSMA-1007 is due to the higher amount of activity of cyclotron-produced 18F compared to 68Ga-PSMA-11 derived from 68Ge/68Ga generator elution and its higher half-life and higher physical spatial resolution [20]. In addition, 18F-PSMA-1007 has a very low urinary elimination, which is another advantage making it easier to differentiate between local recurrence or lymph node metastases and urinary activity in the ureter or the urinary bladder [15, 21]. Scanning for 18F-PSMA-1007 was performed 120 min and for 68Ga-PSMA-11 60 min p.i. starting at lower limbs to the skull. Patients were asked to empty the bladder before the scan. Images were acquired with a scan time of 3 min per bed position on a Siemens mCT scanner or Siemens PET-MRI (Siemens Healthcare, Knoxville, Tennessee, USA). Image reconstruction was performed using standard manufacturer software. For attenuation correction, a low-dose CT or mRAC was performed in parallel to PET images.

Prebiopsy mpMRI (n = 26) was performed on a 3 T system (Aero and Avanto, Siemens; Germany). The following MRI sequences were analyzed: T2-weighted (T2W) imaging, diffusion-weighted imaging (DFW), apparent diffusion coefficient map (ADC-map), and dynamic contrast-enhanced (DCE) perfusion imaging. Maps of ADC are computed from DWI and provide a quantitative parameter to evaluate prostate regions with suspicion of prostate carcinoma. Multi-vendor digital imaging system “DynaCAD” was used for performing real-time image analysis of prostate MRI (“Sanova Medical Systems”, Austria, Vienna). The receiver coil technology included pelvic phased-array coils without the addition of an endorectal coil. The median b value was 1,700 (range 900–2000). Image data were analyzed using the PIRADS v2.1 classification [22]. Intraprostatic lesions (IPLs) rated as score 4 or greater were selected for a targeted biopsy. Detailed technical description of the mpMRI acquisition protocol is given in [23].

Prostate punch biopsy

In accordance with current guidelines for prostate carcinoma, at least 10–12 puncture specimens were obtained [24, 25]. Most of the analyzed patients (70%) underwent systematic and MRI-targeted biopsies [26–28]. Following prostate biopsy, formalin-fixed, paraffin-embedded tissue samples were cut into 4-μm-thick sections, prepared on slides, and stained with hematoxylin and eosin. Gleason-score and tumor extent were reported for each localization following the clinical practice guidelines [29, 30].

Definition of IPL contours

Delineation of IPLs was performed separately in PSMA-PET/MRI, PSMA-PET/CT and mpMRI images. The IPLs found in the imaging modalities were marked in the PIRADS schemes [22]. It was then checked whether prostate carcinoma had also been found in these regions in the diagnostic biopsies (Fig. 1, “Supplemental data”).

Manual registration of the PIRADS-Map and the PET/CT or MRI was performed with different software tools. At the beginning, the landmarks were sliced in the axial images and divided into 12 segments at each of the apex, mid and base prostate region. The axial slice of PET/CT (5-mm slice thickness) or MRI (3-mm slice thickness) visualizing the apex, mid or base prostate region of the PIRAD schemes were selected and exported to GIMP 2.10.14 (free GNU Image Manipulation Program). A difference in image size was corrected and the slices were registered. The first step of registration is a rigid registration. Only translation and rotational manipulation is, therefore, allowed. This registered image pair was then exported to Adobe Illustrator CS5 (Adobe Systems Incorporated; San Jose, CA, USA). Anatomical differences between the patient PET/CT or MRI and the standard PIRAD-Map were corrected in a second step using multipoint deformation. For this the contour of the apex, mid or base prostate region of the PIRAD-Maps were selected and multi-deformation-points at the contour were added. By selecting the deformation points at the contour, the whole PIRAD-Map was deformed. This deformation was finished when the PIRAD-Map and the anatomy of the prostate are as close as possible. Two experienced radiation oncologists performed the manual deformation by the matching of PET/CT or MRI images with PIRADS-Map independently. The radiation oncologist’s matchings were verified in blinded conditions by another radiation oncologist. The registration process was performed in two-dimensional accuracy at different axial slices (apex, mid or base prostate region).

Two experienced radiation oncologists and two nuclear medicine physicians were independently involved in the manual contouring of intraprostatic foci on the co-registered PET and MRI scans. We also performed interobserver analyses to account for discrepancies in manual delineation of IPLs. Figure 1 shows the identifying of malignant prostate lesion using the hybrid method 68Ga-PSMA-PET/MRI with separate delineation of prostate focus in PSMA-PET image and different MRI sequences. In addition, the IPLs were identified using the PSMA-PET-based automatic contours, applying the threshold’s set of maximal standardized uptake values (SUV\textsubscript{max}) within the prostate from 40 to 80% [4]. An isotropic line of 5 mm was added to the external margin both of image-defined IPLs and of biopsy contour [22, 31].

For correlation analyses, we selected the dominant IPLs based on the criteria that regard the size and SUV activity of identified intraprostatic foci [32–35]. IPLs with a size of at least 1 cm\(^3\) and a SUV threshold of at least three were defined as dominant IPLs considering that smaller
carcinoma foci expressing low SUV activity may be poorly detected and characterized by PET/CT or MRI techniques.

Correlation analysis

Dice similarity coefficient (DSC), Youden index (YI), sensitivity and specificity were evaluated on the basis of matching between radiological images and biopsy landmarks [14, 36–38]. Detailed description of the correlation parameters is presented in the “Supplemental Data”.

The contouring accuracy was separately evaluated for all images, and received values were averaged and designated as \(68\text{Ga-PSMA-PET/MRI}_{\text{man}}, 18\text{F-PSMA-PET/CT}_{\text{man}}, 68\text{Ga-PSMA-PET/CT}_{\text{man}}, \) and \(\text{mpMRI}_{\text{man}}\). The contouring method showing the highest DSC and YI values was determined as the best automatic contouring method [4].

The following factors that may be predictive for the contouring accuracy were analysed: pre-imaging PSA, prostate biopsy Gleason score (GS), relative IPL volume (percentage of the tumour volume to the total prostate volume), IPL localisation, \(\text{SUV}_{\text{max}}\). For this purpose, the effect of these factors on the DSC results was evaluated [4].

Statistical analysis

The Kolmogorov–Smirnov test and the Kruskal–Wallis tests were used to evaluate abnormally distributed data and to compare the correlation parameters, including DSC, YI, sensitivity and specificity, between PSMA-PET/CT and MRI images. The influence of the following indicators as initial PSA, biopsy GS, tumor volume, tumor localisation, and \(\text{SUV}_{\text{max}}\) on the accuracy of PSMA-PET/CT and mpMRI for identifying the IPLs was analyzed using the Pearson’s Correlation Coefficient. A multivariate logistic regression analysis was performed. The threshold for statistical significance was \(p < 0.05\). As the nature of the study was exploratory, \(p\) values were interpreted from a Bayesian point of view. Statistical analyses were performed using SPSS software (IBM SPSS Statistics 24.0).

Results

Patient and radiological image characteristics are presented in Table 1. Principal agreement for delineating IPLs was observed between the imaging techniques. Localisations of positive biopsies exceeded the IPLs in the majority of patients. Based on the criteria for dominant IPLs, we selected for the correlation analysis 17 prostate lesions identified with \(68\text{Ga-PSMA-PET/MRI}, 33\) IPLs detected with \(18\text{F-PSMA-PET/CT}\) and mpMRI, and 21 IPLs diagnosed with \(68\text{Ga-PSMA-PET/CT}\) and mpMRI (Table 1). Interobserver analysis revealed no relevant variabilities in manual contouring of IPLs.
The correlation indices, including the mean DSC, YI, sensitivity and specificity for each contouring value are summarized in Table 2. SUV70% was defined as the best automatic contouring method showing the highest DSC and YI values both for 68Ga-PSMA-PET/CT and 18F-PSMA-PET/CT. The DSC values for 68Ga-PSMA-PET/CT and 18F-PSMA-PET/CT were found significantly superior compared to mpMRI (p < 0.001). The differences in DSC values between PSMA-PET images, including 68Ga-PSMA-PET/MRI, were not significant. No improvements in DSC values were found by additional use of mpMRI to PSMA-PET techniques (Fig. 2a, Table 2).

In accordance to DSC, the median YIs were found significantly superior for 68Ga-PSMA-PET/CT and 18F-PSMA-PET/CT compared to mpMRI. The median YIs were not improved by additional use of mpMRI (Fig. 2a, Table 2). The sensitivity and specificity, as expected, showed the correlation with YI (Table 2). A trend to the higher specificity was found for 68Ga-PSMA-PET/MRI (97%, p = 0.19) compared to 18F-PSMA-PET/CT (93%) or 68Ga-PSMA-PET/CT (92%) (Table 2). The mpMRI revealed the lower sensitivity (45%, p < 0.001) and a tendency to higher specificity (96%, p = 0.24) compared to 18F-PSMA-PET/CT or 68Ga-PSMA-PET/CT techniques (Fig. 2b).

As demonstrated in Table 3, IPL localisation and relative IPL volume were found as factors significantly predicting the accuracy of PSMA-PET/CT and mpMRI for localizing the IPLs. Superior diagnostic accuracy was found for lesions with a minimal relative volume of 15%. 18F-PSMA-PET/CT showed higher diagnostic performance than 68Ga-PSMA-PET/CT for lesions localized in transition zone of the base region (0.67 vs. 0.56, correspondingly, p = 0.003). The differences in correlation results between 68Ga-PSMA-PET/CT and 18F-PSMA-PET/CT in mid and apex regions was not significant. Diagnostic accuracy of IPLs with GS 7b was superior to GS 6 and 7a (p < 0.05). The pre-imaging PSA and SUVmax showed no effect on diagnostic performance of PSMA-PET/CT tools.

**Discussion**

This study evaluates the diagnostic accuracy of PSMA-PET-based technologies as well as mpMRI for localizing IPLs using prostate biopsy specimens as standard of

| Table 2 | Correlation indices evaluated by the co-registration of PSMA-PET and MRI images with biopsy specimens |
|------------------|---------------------------------|-----------------|-----------------|-----------------|
| **Parameter** | **SUV3.0, 68Ga-PSMA-PET/CT** | **SUV70%, 68Ga-PSMA-PET/MRI** | **SUV70%, 68Ga-PSMA-PET/CT + mpMRIman** | **mpMRIman** |
| **DSC** | 0.42 ± 0.17 | 0.61 ± 0.21 | 0.59 ± 0.24 | 0.47 ± 0.13a |
| **YI** | 0.33 ± 0.14 | 0.50 ± 0.18 | 0.50 ± 0.23 | 0.41 ± 0.16b |
| **Sensitivity (%)** | 57 ± 9 | 79 ± 17 | 61 ± 13 | 45 ± 9c |
| **Specificity (%)** | 88 ± 18 | 97 ± 17 | 96 ± 11 | 96 ± 9 |

Values are given with ± standard deviation

DSC Dice similarity coefficient, mpMRIman multiparametric magnetic resonance imaging (MRI) manual contour, 68Ga-18F-PSMA 68Gallium-18Fluoromethylcholine-prostate specific membrane antigen, PETman positron emission tomography/manual contouring, SUVstandard uptake value, YI Youden index

aDSC mpMRIman vs. 68Ga-PSMA-PET/MRIman. 68Ga-PSMA-PET/CT + mpMRIman, and 18F-PSMA-PET/CT + mpMRIman (p < 0.001)
bYI mpMRIman vs. 68Ga-PSMA-PET/MRIman. 68Ga-PSMA-PET/CT + mpMRIman, and 18F-PSMA-PET/CT + mpMRIman (p < 0.001)
cSensitivity mpMRIman vs. 68Ga-PSMA-PET/MRIman. 68Ga-PSMA-PET/CT + mpMRIman, and 18F-PSMA-PET/CT + mpMRIman (p < 0.001)
Eiber and colleagues revealed significant superiority for $^{68}$Ga-PSMA-PET/MRI compared to separate PET/CT and mpMRI techniques for delineating malignant intraprostatic
Our results show no relevant difference in accuracy for delineating IPLs between $^{68}$Ga-PSMA-PET/CT and $^{18}$F-PSMA-PET/CT and $^{68}$Ga-PSMA-PET/MRI. However, a trend to superior specificity was seen using the hybrid method. This discrepancy can be explained given different radiological and morphological criteria for the definition of dominant or malignant IPLs between the studies. In detail, Eiber et al. differentiated the malignancy of IPLs in PET and MRI images using 5-point Likert scale [6]. Based on the criteria for superior malignancy of intraprostatic foci, we selected dominant lesions with a SUV threshold of at least 3 and size of at least 1 cm$^3$ considering that smaller carcinoma foci expressing low SUV activity do not determine the risk of local relapse after prostatectomy and may be poorly detected and described by PET/CT or MRI techniques [14, 32–35]. Second, manual contouring of IPLs as a subjective method can also provoke the deviations in correlation results across the studies. To reduce the inaccuracy through the manual contouring, we generated the automatic contours based on the thresholds set of the SUVmax values inside the prostate as described by Chang et al. [4]. In addition, the correlation analyses can be affected through inaccuracy in co-registration proceeding between images and histological landmarks. Advanced software providing the registration with minimal deformation of image scans and landmarks should be analysed in further studies. Despite some diagnostic limitations, the mpMRI was recommended in several guidelines as staging method as well as method for targeted biopsy in the diagnostic of primary PCa [26–28, 39–44].

### Table 3 Factors predicting the accuracy of PSMA-PET techniques and mpMRI for delineating IPLs

| Parameter          | $^{18}$F-PSMA-PET/CT | $^{68}$Ga-PSMA-PET/CT | $^{68}$Ga-PSMA-PET/MRI | mpMRI |
|--------------------|-----------------------|-----------------------|------------------------|-------|
|                    | $r$ | $p$     | $r$ | $p$      | $r$ | $p$     | $r$ | $p$     |
| Apex               | 0.18 | 0.42 | 0.15 | 0.29 | 0.24 | 0.37 | 0.12 | 0.53 |
| Mid                | 0.35 | 0.24 | 0.12 | 0.47 | 0.19 | 0.45 | 0.17 | 0.39 |
| Base               | 0.92 | 0.03 | 0.43 | 0.21 | 0.46 | 0.24 | 0.14 | 0.42 |
| IPL volume$^b$     |       |       |       |       |       |       |       |       |
| ≤ 5%               | 0.22 | 0.36 | 0.27 | 0.41 | 0.25 | 0.28 | 0.19 | 0.41 |
| ≤ 10%              | 0.64 | 0.13 | 0.68 | 0.09 | 0.71 | 0.11 | 0.52 | 0.22 |
| ≤ 15%              | 0.92 | 0.02 | 0.93 | 0.02 | 0.94 | 0.03 | 0.67 | 0.09 |
| ≤ 20%              | 0.96 | 0.01 | 0.96 | <0.01 | 0.97 | <0.01 | 0.84 | 0.04 $^a$ |
| Gleason score      |       |       |       |       |       |       |       |       |
| 6                  | 0.18 | 0.45 | 0.24 | 0.36 | 0.26 | 0.30 | 0.13 | 0.41 |
| 7a                 | 0.38 | 0.20 | 0.43 | 0.17 | 0.53 | 0.09 | 0.31 | 0.27 |
| 7b                 | 0.79 | 0.05 | 0.81 | 0.04 $^a$ | 0.84 | 0.03 $^a$ | 0.56 | 0.17 |
| 8                  | 0.87 | 0.04 | 0.90 | 0.03 $^a$ | 0.92 | 0.02 $^a$ | 0.81 | 0.07 |
| Pre-imaging PSA (ng/mL) |       |       |       |       |       |       |       |       |
| ≤ 10               | 0.27 | 0.32 | 0.18 | 0.35 | 0.34 | 0.23 | 0.21 | 0.24 |
| 10–20              | 0.30 | 0.37 | 0.33 | 0.26 | 0.28 | 0.52 | 0.19 | 0.41 |
| > 20               | 0.37 | 0.29 | 0.25 | 0.41 | 0.46 | 0.17 | 0.27 | 0.37 |
| SUV$^{\text{max}}$ |       |       |       |       |       |       |       |       |
| 2                  | 0.31 | 0.23 | 0.25 | 0.35 | 0.27 | 0.26 | – | – |
| 3                  | 0.28 | 0.40 | 0.23 | 0.28 | 0.36 | 0.21 | – | – |
| ≥ 4                | 0.44 | 0.15 | 0.37 | 0.20 | 0.33 | 0.30 | – | – |

$^{68}$Ga/$^{18}$F-PSMA $^{68}$Gallium/$^{18}$Fluoromethylcholine-prostate specific membrane antigen, PET positron emission tomography, mpMRI multi-parametric magnetic resonance imaging, IPL intraprostatic lesion, $r$ Pearson’s Correlation Coefficient, PSA prostate specific antigen, SUV$^{\text{max}}$ maximal standardized uptake value

$^a$5% level of significance

$^b$Relative to the whole prostate volume
results and diagnostic mpMRI can be expected for patients with the MRI-derived prostate biopsies.

As demonstrated in previous studies, the rate of not detected intraprostatic foci by separate use of MRI-targeted biopsy and systematic biopsy remains relatively high (up to 20%) [26–28]. Superior detection rate can be achieved by combined use of systematic biopsy and MRI-targeted biopsy [26–28]. For this reason, we used a combination of both biopsy modes in the most of analysed patients (70%) reducing the risk of not detected prostate carcinoma foci. In accordance to several previous studies, we performed the correlation analysis using the “section model” [1–3, 6–8]. Alternatively, a “voxel model” was recommended by another group of authors [4, 14, 31]. Using the much more voxels per prostate volume, superior delineation of IPLs can be potentially achieved. However, the section model seems to be more compatible to the two-dimensional registration between images and histological specimens performed in our study. And the studies where the voxel model was used, a three-dimensional registration were performed. Prostatectomy specimens may serve as a more conclusive reference, as previous studies localized IPLs on 3–5 mm transverse slice of the prostate [4, 7, 8, 14]. This provided a better diagnostic performance compared to biopsy-based investigations such as the present study where the landmarks were sliced in the axial images and divided into 12 segments at each of the apex, mid and base prostate region. However, obtaining biopsy specimens is the most promising reference in evaluating IPLs in non-surgical radiotherapy treatment regimens given the absence of whole-organ prostatectomy specimens. To our opinion, the combination of histological landmarks generated on the basis of MRI-targeted and systemic biopsies with advanced PSMA-PET/MRI or PET/CT technologies can be recommended for localizing malignant prostate foci.

The IPL localization and volume, as well as GS were found as factors predicting the accuracy of PSMA-PET/CT and mpMRI for delineating IPLs. Strong positive correlation with DSC was observed for prostate foci localized in the base region and not in mid or apex regions. Thus, significantly higher correlation was found for 18F-PSMA-PET/CT versus 68Ga-PSMA-PET/CT localizing the IPLs in transition zone of the base region. This phenomenon can be explained by lack of physiological SUV-activity in urinary bladder using the radioligand 18F-PSMA in contrast to 68Ga-PSMA. Large lesions and high GS showed superior correlation outcome both for PSMA-PET/CT and mpMRI techniques. Thus, the PET/CT and MRI methods showed superior diagnostic accuracy of prostate lesions with at least 15% of prostate volume and GS 7b and higher. Similarly, Eiber and colleagues showed superior diagnostic score for prostate foci > 5 mm and GS ≥ 7 using the hybrid method 68Ga-PSMA-PET/MRI [6]. As known from the literature, diagnostic performance of primary or recurrent prostate cancer by PET or MRI techniques is in positive correlation with absolute PSA values [5, 10, 45]. In contrast, we showed no positive correlation between PSA values and diagnostic performance of PSMA-PET/CT or mpMRI. This result can be related with discrepancy between PSA level and grade of GS in about 20% of cases. These patients revealed the GS 7b or 8 by PSA values not exceeding 10 ng/mL. In the same manner, Eiber et al. showed no effect of PSA on diagnostic quality of PSMA-PET/CT for localizing the IPLs [6].

Several trials validated the efficiency of PET/CT-based approaches for RT planning using focal dose escalation on intraprostatic tumour areas [7, 8, 46–49]. The results reported here show that all analyzed PSMA-PET-based methods, inclusive the hybrid method 68Ga-PSMA-PET/ MRI, seem to be accurate for delineating malignant IPLs. Importantly, this is the first study that uses biopsy specimens as the standard of reference for identifying IPLs. To facilitate this, we specifically designed biopsy-derived PIRAD-Maps that can be used as reference models for localizing the IPLs. The second crucial question concerns the selection criteria for dominant IPLs. It is known that both SUV activity and the size of intraprostatic foci determine the malignancy of IPLs. However, the threshold values for both of these parameters for selection of dominant IPLs are not precisely defined. An addition, it is not clear, if the focal boost treatment of the prostate lesions selected in PSMA-PET/CT would have a therapeutic advantage for reducing the risk of local relapse compared to the boost applying to the whole prostate. Particular relevance for focal dose escalation may have the prostate lesions showing the PSMA uptake after initiation of androgen deprivation therapy. In this perspective, optimisation in selection of dominant IPLs, biopsy guidelines, design of biopsy-derived landmarks, and technologies for registration of images and biopsy landmarks should be evaluated in further studies.

Summarizing the key findings of this study: (1) PSMA-PET/CT revealed superior diagnostic accuracy for delineating IPLs as compared to mpMRI; (2) no improvement in diagnostics of IPLs was shown by combined use of PSMA-PET/CT and mpMRI compared to PSMA-PET/CT alone; (3) no significant difference in diagnostic accuracy was observed between the hybrid method 68Ga-PSMA-PET/MRI and separate techniques 18F-PSMA-PET/CT and 68Ga-PSMA-PET/CT; however, the hybrid method showed a trend to a higher diagnostic specificity; (4) superior diagnostic performance for 18F-PSMA-PET/CT versus 68Ga-PSMA-PET/CT was found for lesions localized in the base region; and (5) the volume of lesions and the grade of GS showed a positive correlation with diagnostic accuracy of PSMA-PET/CT and mpMRI.

The limitations of this study are: (1) heterogeneous cohort of selected patients; (2) results can be affected by use of
manual contouring of IPLs; and (3) it does suffer from inaccuracy during co-registration between imaging and biopsy landmarks.

**Conclusion**

The PSMA-PET bears superior contouring of prostate lesions than mpMRI. No improvement for delineating IPLs was received by combination of PSMA-PET/CT and mpMRI compared to PSMA-PET/CT alone. Both PSMA-PET/CT and PSMA-PET/MRI techniques deliver high diagnostic effectiveness for localizing the IPLs, without relevant differences between separate and hybrid methods. Positive correlation between diagnostic accuracy and tumor size as well as tumor GS was observed.

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1007/s12149-021-01606-7.

**Funding** Open Access funding enabled and organized by Projekt DEAL.

**Declarations**

**Conflict of interest** There are no conflict of interest.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Yamaguchi T, Lee J, Uemura H, Sasaki T, Takahashi N, Oka T, Shirzukiishi K, Endou H, Kubota Y, Inoue T. Prostate cancer: a comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy. Eur J Nucl Med Mol Imaging. 2005;32:742–8. https://doi.org/10.1007/s00259-004-1755-y.

2. Testa C, Schiaviara R, Lodi R, Salizzoni E, Corti B, Valsmad M, Kurhanewicz J, Manferrari F, Brunocilla E, Tornob C, Monetti M, Castellucci P, Santi S, Ceo M, Grigioni W, Martorana G, Canini R, Barbiroli B. Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT. Radiology. 2007;244:797–806. https://doi.org/10.1148/radiol.2443071603.

3. Van den Bergh L, Koole M, Iseaert S, Joniau S, Deroose CM, Oyen R, Lerut E, Budiharto T, Mottaghy F, Bormans G, Van Poppel H, Haustermans K. Is there an additional value of 11C-choline PET/CT to T2-weighted MRI images in the localization of intraprostatic tumor nodules? Int J Radiat Oncol Biol Phys. 2012;83:1486–92. https://doi.org/10.1016/j.ijrobp.2011.10.046.

4. Chang JH, Lim Joon D, Davis ID, Lee ST, Hiew CY, Esler S, Gong SJ, Wada M, Clouston D, Sullivan R, Goh YP, Bolton D, Scott AM, Khoo V. Comparison of [(11)C]choline positron emission tomography with T2- and diffusion-weighted magnetic resonance imaging for delineating malignant intraprostatic lesions. Int J Radiat Oncol Biol Phys. 2015;92:438–45. https://doi.org/10.1016/j.ijrobp.2015.02.004.

5. Kesch C, Vinsensia M, Radtke JP, Schlemmer HP, Heller M, Ellert E, Holland-Leitz T, Duensing S, Grabe N, Afshar-Oromieh A, Wieczorek K, Schafer M, Neels OC, Cardinale J, Kratochwil C, Hohenfellner M, Kopka K, Haberkurz U, Hadaschik BA, Giesel FL. Intraindividual comparison of 68Ga-PSMA-1007 PET/CT, multiparametric MRI, and radical prostatectomy specimens in patients with primary prostate cancer: a retrospective, Proof-of-Concept Study. J Nucl Med. 2017;58:1805–10. https://doi.org/10.2967/jnumed.116.189233.

6. Eiber M, Weirich G, Holzapfel K, Souvatzoglou M, Haller B, Rauscher I, Beer AJ, Wester HJ, Gschwend J, Schwaiger M, Maurer T. Simultaneous 68Ga-PSMA-HBED-CC PET/MRI improves the localization of primary prostate cancer, Eur Urol. 2016;70:829–36. https://doi.org/10.1016/j.euro.2015.

7. Bettermann AS, Zamboglou C, Kiefer S, Jilg CA, Spohn S, Kranz-Rudolph J, Fassbender TF, Brossert P, Nicolay NH, Gratzeck C, Bock M, Ruf J, Benndorf M, Grosu AL. 68Ga-PSMA-11 PET/CT and multiparametric MRI for gross tumor volume delineation in a slice by slice analysis with whole mount histopathology as a reference standard—implications for focal radiotherapy planning in primary prostate cancer. Radiother Oncol. 2019;141:214–9. https://doi.org/10.1016/j.radonc.2019.07.005.

8. Zamboglou C, Fassbender TF, Steffan L, Schiller F, Fechter T, Carles M, Kiefer S, Rischke HC, Reichel K, Schmidt-Hegemann NS, Ilhan H, Chirindel AF, Nicholas G, Henkenberens C, Derlin T, Brossert P, Mavroidis P, Chen RC, Meyer PT, Ruf J, Grosu AL. Validation of different PSMA-PET/CT-based contouring techniques for intraprostatic tumor definition using histopathology as standard of reference. Radiother Oncol. 2019;141:208–13. https://doi.org/10.1016/j.radonc.2019.07.002.

9. Malaspina S, De Giorgi U, Kemppainen J, Del Sole A, Paganelli G. 68Ga-PSMA-PET: added value and future applications in comparison to the current use of choline-PET and mpMRI in the workup of prostate cancer. Radiol Med. 2018;123:952–65. https://doi.org/10.1016/j.rmed.2018.09.029.

10. Evangelista L, Briganti A, Fanti S, Joniau S, Reske S, Schiaviara R, Stief C, Thalmann GN, Picchio M. New clinical indications for (18)F/(11)C-choline, new tracers for positron emission tomography and a promising hybrid device for prostate cancer staging: a systematic review of the literature. Eur Urol. 2016;70:161–75. https://doi.org/10.1016/j.euro.2016.01.029.

11. Afshar-Oromieh A, Haberkourn U, Schlemmer HP, Fenchel M, Eder M, Eisenhut M, Hadaschik BA, Kopp-Schneider A, Röthke M. Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur J Nucl Med Mol Imaging. 2014;41:887–97. https://doi.org/10.1007/s00259-013-2660-z.

12. Hartenbach M, Hartenbach S, Bechtloff W, Danz B, Kraft K, Klemenz B, Sparwasser C, Hacker M. Combined PET/MRI improves diagnostic accuracy in patients with prostate cancer: a prospective diagnostic trial. Clin Cancer Res. 2014;20:3244–53. https://doi.org/10.1158/1078-0432.CCR-13-2653.

13. Kim YI, Cheon GJ, Paeng JC, Cho JY, Kwak C, Kang KW, Chung JK, Kim EE, Lee DS. Usefulness of MRI-assisted metabolic volumetric parameters provided by simultaneous (18)F-fluorocholine PET/MRI for primary prostate cancer characterization. Eur J Nucl Med Mol Imaging. 2020;47:654–64. https://doi.org/10.1007/s00259-019-04692-z.
Med Mol Imaging. 2015;42:1247–56. https://doi.org/10.1007/s00259-015-3026-5.

14. Chang JH, Joon DL, Lee ST, Gong SJ, Scott AM, Davis ID, Clouston D, Bolton D, Hamilton CS, Khoo V. Histopathological correlation of (11)C-choline PET scans for target volume definition in radical prostate radiotherapy. Radiother Oncol. 2011;99:187–92. https://doi.org/10.1016/j.radonc.2011.03.012.

15. Rahbar K, Afshar-Oromieh A, Seifert R, Wagner S, Schäfers M, Bögemann M, Weckesser M. Diagnostic performance of 18F-PSMA–1007 PET/CT in patients with biochemical recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45:2055–61. https://doi.org/10.1007/s00259-018-4089-x.

16. Rahbar K, Afshar-Oromieh A, Bögemann M, Wagner S, Schäfers M, Stegger L, Weckesser M. 18F-PSMA-1007 PET/CT at 60 and 120 minutes in patients with prostate cancer: bio-distribution, tumour detection and activity kinetics. Eur J Nucl Med Mol Imaging. 2018;45:1329–34. https://doi.org/10.1007/s00259-018-3989-0.

17. Cardinale J, Schäfer M, Benešová M, Bauder-Wüst U, Leotta K, Eder M, Neels OC, Haberkorn U, Giesel FL, Kopka K. Preclinical evaluation of 18F-PSMA-1007, a new prostate-specific membrane antigen ligand for prostate cancer imaging. J Nucl Med. 2017;58:425–31. https://doi.org/10.2967/jnumed.116.181768.

18. Rahbar K, Weckesser M, Huss S, Semjonow A, Breyholz HJ, Schrader AJ, Schäfers M, Bögemann M. Correlation of intraprostatic tumor extent with 68Ga-PSMA distribution in patients with prostate cancer. J Nucl Med. 2016;57:563–7. https://doi.org/10.2967/jnumed.15.169243.

19. Afshar-Oromieh A, Hetzeheim H, Kratochwil C, Benešová M, Eder M, Neels OC, Eisenhut M, Kübler W, Holland-Letz T, Giesel FL, Mier W, Kopka K, Haberkorn U. The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiations dosimetry, and first evaluation of tumor lesions. J Nucl Med. 2015;56:1697–705. https://doi.org/10.2967/jnumed.15.1611299.

20. Kesch C, Kratochwil C, Mier W, Kopka K, Giesel FL. 68Ga or 18F for prostate cancer imaging? J Nucl Med. 2017;58:687–8. https://doi.org/10.2967/jnumed.117.190157.

21. Rahbar K, Weckesser M, Ahmadvandehfar H, Schäfers M, Stegger L, Bögemann M. Advantage of 18 F-PSMA-1007 over 68Ga-PSMA-11 PET imaging for differentiation of local recurrence vs. urinary tracer excretion. Eur J Nucl Med Mol Imaging. 2018;45:1076–7. https://doi.org/10.1007/s00259-018-3952-0.

22. Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ, Tempany CM, Choyke PL, Cornud F, MargoM, Maier SE, Tempany CM. Multiparametric MRI of prostate cancer: some recommendations for target delineation in radiation oncology. Radiother Oncol. 2010;96:302–7. https://doi.org/10.1016/j.radonc.2009.07.003.

23. Zaidi H, El Naqa I. PET-guided delineation of radiation therapy treatment volumes: a survey of image segmentation techniques. Eur J Nucl Med Mol Imaging. 2010;37:2165–69. https://doi.org/10.1007/s00259-010-1427-x.

24. Hoeks CM, Barentsz JO, Hambrock T, Yakar D, Somfodi DM, Heijmink SW, Scheenen TW, Ves PC, Huisman H, van Oort IM, Wijte JA, Heerschap A, Fütterer JJ. Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology. 2011;261:46–66. https://doi.org/10.1148/radiol.11091822.

25. National Comprehensive Cancer Network (NCCN), Prostate Cancer Early Detection. Clinical Practice Guidelines in Oncology. V.2.2007. Port Washington: NCCN.

26. National Collaborating Centre for Cancer and National Institute for Health and Clinical Excellence (NICE), Prostate Cancer: diagnosis and treatment. 2008.

27. Prost K, Edelsohn H, Cronin B, Dany J, Lannier P. Magnetic resonance-ultrasound fusion biopsy: the role of systematic and targeted biopsies. Cancer. 2016;122:884–92. https://doi.org/10.1002/cncr.29874.

28. Turkbey B, Reisberg SA, Sohaila SA, Charles-Edwards EM, Bhatar S, Christmas TJ, Thompson AC, Bailey MJ, Corbishley CM, Fischer C, Leach M, Deaurnal DP. Dynamic contrast-enhanced MRI for prostate cancer localization. Br J Radiol. 2009;82:143–56. https://doi.org/10.1259/bjr/89518905.

29. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med. 2007;48:932–45. https://doi.org/10.2967/jnumed.106.035774.

30. Khalaf M, Abdel-Nabi H, Baker J, Shao Y, Lamonica D, Gona J. Relation between nodule size and 18F-FDG-PET SUV for malignant and benign pulmonary nodules. J Hematol Oncol. 2008;1:13. https://doi.org/10.1186/1756-8722-1-13.

31. Filson CP, Natarajan S, Margolis DJ, Huang J, Lieu P, Dorey FJ, Reiter RE, Marks LS. Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: the role of systematic and targeted biopsies. Cancer. 2016;122:884–92. https://doi.org/10.1002/cncr.29874.

32. Porpiglia F, De Luca S, Passera R, Manfredi M, Mele F, Bollito E, De Pascale A, Cossu M, Aimar R, Velti A. Multiparametric-magnetic resonance/ultrasound fusion targeted prostate biopsy improves agreement between biopsy and radical prostatectomy Gleason score. Anticancer Res. 2016;36:4833–9. https://doi.org/10.21873/anticancer.110495.

33. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL. Update on the Gleason grading system for prostate cancer: results of an international consensus conference of urologic pathologists. Adv Anat Pathol. 2006;13:53–7. https://doi.org/10.1097/01.pap.000002017.78917.18.

34. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. jnccn.org/view/journals/jnccn/17/5/article-p479.xml. Accessed 1 May 2019.

35. Groenendaal G, Moman MR, Korporaal JG, van Diest PJ, van Vulpen M, Philpamnes MM, van der Heide UA. Validation of functional imaging with pathology for tumor delineation in the prostate. Radiother Oncol. 2010;94:145–50. https://doi.org/10.1016/j.radonc.2009.12.034.

36. Cardinale J, Schäfer M, Benešová M, Bauder-Wüst U, Leotta K, Eder M, Neels OC, Eisenhut M, Kübler W, Holland-Letz T, Giesel FL, Mier W, Kopka K, Haberkorn U. The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiations dosimetry, and first evaluation of tumor lesions. J Nucl Med. 2015;56:1697–705. https://doi.org/10.2967/jnumed.15.1611299.

37. Zaidi H, El Naqa I. PET-guided delineation of radiation therapy treatment volumes: a survey of image segmentation techniques. Eur J Nucl Med Mol Imaging. 2010;37:2165–69. https://doi.org/10.1007/s00259-010-1423-3.

38. Hoeks CM, Barentsz JO, Hambrock T, Yakar D, Somfodi DM, Heijmink SW, Scheenen TW, Ves PC, Huisman H, van Oort IM, Wijte JA, Heerschap A, Fütterer JJ. Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology. 2011;261:46–66. https://doi.org/10.1148/radiol.11091822.

39. Zaidi H, El Naqa I. PET-guided delineation of radiation therapy treatment volumes: a survey of image segmentation techniques. Eur J Nucl Med Mol Imaging. 2010;37:2165–69. https://doi.org/10.1007/s00259-010-1423-3.

40. Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Hambrock T, Yakar D, Somfodi DM, Heijmink SW, Scheenen TW, Ves PC, Huisman H, van Oort IM, Wijte JA, Heerschap A, Fütterer JJ. Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology. 2011;261:46–66. https://doi.org/10.1148/radiol.11091822.
R, Puech P, Punwani S, Sohaib AS, Tombal B, Villers A, van der Meulen J, Emberton M. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol. 2011;59:477–94. https://doi.org/10.1016/j.eururo.2010.12.009.

42. Padgett KR, Swallen A, Pirozzi S, Piper J, Chinea FM, Abramowitz MC, Nelson A, Pollack A, Stoyanova R. Towards a universal MRI atlas of the prostate and prostate zones: comparison of MRI vendor and image acquisition parameters. Strahlenther Onkol. 2019;195(2):121–30. https://doi.org/10.1007/s00066-018-1348-5.

43. Zavala-Romero O, Breto AL, Xu IR, Gautney N, Dal Pra A, Abramowitz MC, Pollack A, Stoyanova R. Segmentation of prostate and prostate zones using deep learning: a multi-MRI vendor analysis [published online ahead of print, 2020 Mar 27]. Strahlenther Onkol. 2020. https://doi.org/10.1007/s00066-020-01607-x.

44. Daniel M, Kuess P, Andrzejewski P, Nyholm T, Helbich T, Polanec S, Dragschitz F, Goldner G, Georg D, Baltzer P. Impact of androgen deprivation therapy on apparent diffusion coefficient and T2w MRI for histogram and texture analysis with respect to focal radiotherapy of prostate cancer. Strahlenther Onkol. 2019;195(5):402–11. https://doi.org/10.1007/s00066-018-1402-3.

45. Beaulieu K, Shanbrun L. Is there a correlation between Prostate Specific Antigen (PSA) and imaging modalities that may aid in detecting disease progression in patients with prostate cancer post prostatectomy? J Nucl Med. 2019;60:2065.

46. Pinkawa M, Holy R, Piroth MD, Klotz J, Nussen S, Krohn T, Mottaghy FM, Weibrecht M, Eble MJ. Intensity-modulated radiotherapy for prostate cancer implementing molecular imaging with 18F-choline PET-CT to define a simultaneous integrated boost. Strahlenther Onkol. 2010;186(11):600–6. https://doi.org/10.1007/s00066-010-2122-5.

47. Schlenter M, Berneking V, Krenkel B, Mottaghy FM, Vogeli TA, Eble MJ, Pinkawa M. Intensity-modulated radiotherapy of prostate cancer with simultaneous integrated boost after molecular imaging with 18F-choline-PET/CT: clinical results and quality of life. Strahlenther Onkol. 2018;194(7):638–45. https://doi.org/10.1007/s00066-018-1282-6.

48. Pinkawa M, Piroth MD, Holy R, Klotz J, Djukic V, Corral NE, Caffaro M, Winz OH, Krohn T, Mottaghy FM, Eble MJ. Dose-escalation using intensity-modulated radiotherapy for prostate cancer—evaluation of quality of life with and without (18)F-choline PET-CT detected simultaneous integrated boost. Radiat Oncol. 2012;7:14. https://doi.org/10.1186/1748-717X-7-14.

49. Zamboglou C, Thomann B, Koubar K, Bronsert P, Krauss T, Rischke HC, Sachpazidis I, Drendel V, Salman N, Reichel K, Jilg CA, Werner M, Meyer PT, Bock M, Baltas D, Grosu AL. Focal dose escalation for prostate cancer using 68Ga-HBED-CC PSMA PET/CT and MRI: a planning study based on histology reference. Radiat Oncol. 2018;13:81. https://doi.org/10.1186/s13014-018-1036-8.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.